CSL Limited
CSL.AXHealthcareASXBiotechnology
Scan Results
Daily timeframeCSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom,. At a $46.02B market cap, CSL Limited ranks as a large-cap company within healthcare. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments.
Market Cap
$46.02B
Beta
0.14
P/E (TTM)
11.16
P/E (Fwd)
10.52
EPS (TTM)
$8.61
EPS (Fwd)
$9.13
ROE
6.7%
ROA
6.6%
Cash
$1.14B
Total Debt
$11.14B
Free CF
$1.85B
52W Change
-60.5%
Annual Financials
Cash vs Debt
CSL Limited carries $11.14B in total debt against $1.14B in cash reserves — debt is roughly 9.7x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $1.85B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 6.7%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $10.49B (2022) to $15.43B (2025), reflecting a 47% increase over the period.
With a beta below 0.7, CSL Limited typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CSL.AX.